Global Expert Perspectives: Metastatic Renal Cell Carcinoma - Episode 8
There are different approaches for overcoming resistance in metastatic renal cell carcinoma (mRCC), states Bernard Escudier, MD. One approach is to target some of the cytokines; another is to target fibroblast growth factor (FGF). Lenvatinib, which inhibits FGF and VEGF, has been tested to try to overcome resistance in mRCC.
In a three-arm phase II study, lenvatinib in combination with everolimus improved progression-free survival by more than 7 months when compared with lenvatinib alone. Lenvatinib has a broad range of targets, says Susanne Osanto, MD. Phase III data are needed to confirm the efficacy in combination with everolimus. However, there tends to be a need to dose-reduce and/or interrupt treatment due to the toxicities with lenvatinib, notes Escudier.